Valamor (Ribociclib) and Faslodex (Fulvestrant) Treatment in Advanced Breast Cancer
Reading tools
In this article
💊 Definition and Clinical Efficacy
- Combination: ribociclib with fulvestrant is used in suitable patients either initially or after progression on previous hormone therapy. Ovarian suppression should be added in eligible premenopausal and perimenopausal women.
- Clinical benefit: MONALEESA-3 phase III showed OS and PFS superiority; extended 1L subgroup analyses reported long OS (≈5–6 years) and delayed chemotherapy.
- Treatment goal: prolong life, improve quality of life, and reduce symptoms such as pain and fatigue.
🧾 FDA-Approved Indications
- Ribociclib: with an aromatase inhibitor or fulvestrant in HR+/HER2− advanced/metastatic breast cancer, either as initial endocrine-based treatment or after progression on endocrine therapy.
- Fulvestrant: alone or within endocrine-based combinations in hormone receptor-positive advanced or metastatic breast cancer, 500 mg intramuscularly
Ovarian suppression is recommended when used with an aromatase inhibitor or fulvestrant in premenopausal and perimenopausal women and in men.
⚙️ Mechanism of Action
Ribociclib
- Inhibits cyclin-dependent kinases (CDK) 4 and 6, preventing retinoblastoma protein hyperphosphorylation, arresting the cell cycle in the first gap phase, and reducing tumor cell proliferation.
- May act synergistically when given with endocrine pathway suppression.
Fulvestrant
- Strongly blocks the estrogen receptor and promotes its degradation, suppressing estrogen-dependent gene expression and tumor cell proliferation.
- Given as a depot intramuscular injection at regular intervals.
📐 Guideline Indications and Treatment Goals
- NCCN/ESMO: Endocrine therapy combined with cyclin-dependent kinase 4 and 6 inhibitors is among the preferred options for hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic disease. Ribociclib + fulvestrant is a recommended combination either initially or after progression.
- Goals: OS/PFS, organ preservation, symptom control, delaying chemotherapy, minimizing toxicity.
💉 Dosing and Administration
| Drug | Standard Schedule | Administration Details |
|---|---|---|
| Ribociclib (Valamor) | 600 mg daily for 21 consecutive days, followed by a 7-day break; one cycle every 28 days. | Take at the same time each day, with or without food. Swallow tablets whole with water; do not crush, split, or chew. |
| Fulvestrant | 500 mg total intramuscularly, with a syringe into each buttock delivering 250 per site on the first day, day 15, and day 29; then every 28 days. | Inject slowly into muscle, over approximately one to two minutes per syringe. Rotate injection sites. |
| Ovarian suppression | Added in eligible premenopausal and perimenopausal women. | Given regularly at intervals specified by the institutional protocol. |
| Doses and intervals follow product information; minor differences may occur according to institutional protocols. | ||
💊 Using Valamor (Ribociclib)
Daily routine
- Choose and maintain the same time each day. If taking multiple tablets, take them all together.
- May be taken with or without food; a light meal may improve tolerability if stomach discomfort occurs.
- If you realize on the same day that you missed a dose, skip it and return to the scheduled time the next day. Do not take an additional dose that day after vomiting.
- Phone reminders and weekly pill organizers can improve daily adherence.
Food and storage
- Avoid grapefruit and grapefruit juice because of interaction risk.
- Avoid herbal products containing St. John's wort.
- Store in the original packaging at room temperature, away from moisture and out of children's reach.
- Carry it in hand luggage when traveling, and adjust your daily time to the new time zone when visiting countries with a time difference.
Monitoring Schedule and Laboratory Assessment
- Plan ECGs before treatment, around day 14 of the first cycle, and at the start of the second cycle. Repeat as needed.
- Check electrolytes such as potassium, calcium, magnesium, and phosphorus at baseline and at the start of the first 6 cycles.
- Assess blood counts and liver function every two weeks during the first 2 cycles, then at least monthly.
🧪 Before Treatment and at Visits
Before starting treatment
- ECG and electrolytes to assess risk related to the QT interval, which reflects cardiac repolarization.
- Complete blood count, liver enzymes, bilirubin, and renal function.
- Contraception counseling for people at risk of pregnancy.
- A detailed medication and supplement list to screen for interactions.
At every visit
- Ask about symptoms: fever, signs of infection, shortness of breath, palpitations, jaundice, rash.
- Continue or interrupt dosing according to blood counts and liver function.
- Assess fulvestrant injection sites for pain, bruising, and nerve injury; advise ice and pressure when needed.
🔗 Drug Interactions
- Ribociclib is processed by the cytochrome P four hundred fifty-three A four enzyme. Avoid strong inhibitors (e.g., ketoconazole, itraconazole, posaconazole, clarithromycin); if essential, reduce the dose to four hundred milligrams and monitor closely.
- Avoid strong inducers of the same enzyme (e.g., rifampicin, carbamazepine, phenytoin, phenobarbital); efficacy may fall substantially.
- Antiarrhythmics and similar drugs prolonging the ECG QT interval pose a risk; avoid if possible, or monitor ECGs frequently if essential.
- Concurrent tamoxifen is not recommended; adverse effects on cardiac electrical conduction may increase.
- Fulvestrant does not tend to cause significant liver enzyme-mediated interactions, but intramuscular administration requires consideration of bleeding risk in patients taking blood thinners.
🧭 Practical Dose Modification Approach
| Situation | Recommended Approach |
|---|---|
| Starting dose and steps | Start at 600 mg. First reduction: 400 mg; second: 200 mg. Discontinue if a lower dose is needed. |
| Neutropenia | With grade three neutropenia, interrupt treatment; resume at the same dose after recovery to grade two or lower. Recurrent grade three requires a one-step reduction. With febrile grade three or grade four neutropenia, interrupt until grade two and resume one dose step lower. |
| Elevated liver enzymes | For grade three or higher elevations, interrupt until baseline or grade one, then reduce one step. Permanently discontinue if liver enzymes exceed three times normal and bilirubin simultaneously exceeds twice normal without biliary obstruction. |
| QT interval prolongation on ECG | For marked QT prolongation on ECG, interrupt treatment and resume one dose lower after recovery to a safe level. Consider permanent discontinuation for very marked prolongation with fainting or arrhythmia signs. |
| Drug-related lung inflammation | Interrupt for symptomatic grade two or higher; resume at a lower dose after improvement. Discontinue for recurrence or severe cases. |
| Severe skin reactions | Permanently discontinue for suspected Stevens–Johnson syndrome, toxic epidermal necrolysis, or drug reaction with eosinophilia and systemic symptoms. |
| Essential use of a strong enzyme inhibitor | Reduce ribociclib to four hundred milligrams; the previous dose may be resumed after sufficient time following discontinuation of the interacting drug. |
🇹🇷 Licensing in Türkiye & SGK Reimbursement
Ribociclib (Valamor) — License
- Licensed by TİTCK in Türkiye (Valamor 200 mg film-coated tablets; product information/leaflet available).
- Valamor Price: 54.722.61 TL.
Ribociclib (Valamor) — SGK/SUT Reimbursement (Summary)
- Included in the List of Reimbursable Medicines (ANNEX-4/A) for reimbursement.
- After one line and at least 6 months of aromatase inhibitor therapy for metastatic disease, with clinical and/or radiological progression,use with fulvestrant is covered
as is recurrence/metastasis during adjuvant aromatase inhibitor therapy (after at least 12 months) or within 12 months of completing it, whenused with fulvestrantby the Institution.
Use after relapse within the first 12 months of adjuvant aromatase inhibitor therapy, or after more than one aromatase inhibitor line for metastatic disease,is not reimbursed by the Institution.
Endocrine therapy in pre/perimenopausal womenshould be combined with a luteinizing hormone-releasing hormone(LHRH) agonist.
Fulvestrant (Faslodex) — License
- Licensed by TİTCK in Türkiye (500 mg i.m. schedule; product information/leaflet available).
- Faslodex price: 7,099.61 TL.
Fulvestrant (Faslodex) — SGK/SUT Reimbursement (Summary)
- The Institution reimburses combination use with ribociclib or palbociclib after clinical and/or radiological progression following more than 6 months of first-line aromatase inhibitor treatment for recurrent/metastatic breast cancer. It does not reimburse use in patients previously given fulvestrant, relapsing within the first 12 months of adjuvant aromatase inhibitor therapy, or treated with more than one aromatase inhibitor line for metastatic disease.
The Institution reimburses combination use with ribociclib or palbociclib for recurrence/metastasis during adjuvant aromatase inhibitor therapy (after at least 12 months) or within 12 months after completion. It does not reimburse use in patients previously given fulvestrant, relapsing within the first 12 months of adjuvant aromatase inhibitor therapy, or treated with more than one aromatase inhibitor line for metastatic disease. - Reimbursed in hormone receptor-positive, locally advanced or metastatic breast cancer in pre/peri/postmenopausal patients (naturally or artificially induced menopause) recurring during or after endocrine therapy [tamoxifen or an aromatase inhibitor (anastrozole, exemestane, or letrozole)].
🤒 Adverse Effects and Practical Tips
The following illustrative rates are compiled from product information and safety data in large studies.
| Adverse Effect | Estimated Frequency | Practical Approach |
|---|---|---|
| Reduced leukocyte count | approximately 90% or more | Regular blood counts; without symptoms, follow the interruption/reduction algorithm. |
| Neutropenia | severe in approximately one in every 2 people | Fever education; seek emergency care for fever. Growth factors may be considered when needed. |
| Elevated liver enzymes | approximately one in every 2 people | Monitor every two weeks in the first two cycles; interrupt and reduce one step for marked rises. |
| Fatigue | approximately one in 3 | Sleep routine, light exercise, thyroid and anemia assessment. |
| Nausea and vomiting | up to approximately half | Small, frequent meals; antiemetics recommended by your doctor if needed. |
| Diarrhea | approximately 1/3 | Fluids; assess for infection and bowel inflammation if prolonged. |
| Elevated creatinine | approximately 2/5 | Mostly mild and transient; interpret alongside glomerular filtration rate to assess true renal function. |
| Rash | approximately 1/4 | Moisturizers and topical treatments if mild; assessment if severe or widespread. |
| QT interval prolongation on ECG | low rate | Correct electrolytes and avoid concomitant high-risk drugs; discontinue for marked prolongation. |
| Fulvestrant injection-site pain or bruising | variable | Z-track injection, alternating buttocks, ice and pressure advice. |
Emergency warning signs: fever above thirty-eight degrees and chills, jaundice or dark urine, marked shortness of breath and cough, fainting or severe palpitations, widespread blistering rash.
📚 References
- FDA Labels: Kisqali (ribociclib) and Fulvestrant — indications, dosing, monitoring, dose modifications, DDIs, safety.
- MONALEESA-3 phase III publication and extended analyses — OS/PFS benefit with ribociclib + fulvestrant.
- NCCN Breast Cancer (Metastatic HR+/HER2−) — ET + CDK4/6i as the "preferred" 1L approach.
- ESMO Guidelines (HR+/HER2− ABC) — CDK4/6i + ET standard and practical recommendations.
- eviQ and BC Cancer protocols — administration/monitoring and patient education practices.
Was this article helpful?
Your feedback helps us improve our content.
Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.